TIRZEPATIDE 10MG | Weight Loss Dual Agonist

Tirzepatide 10mg is a research-grade GIP/GLP-1 receptor agonist studied for glycaemic control, weight reduction, insulin sensitivity and hepatic fat. This 3 ml vial containing 10 mg presentation is intended for laboratory investigation of mid-range dual incretin studies. Tirzepatide activates GIP and GLP-1 receptors with a fatty-acid modification that extends its half-life to about five days. The dual action increases glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and reduces appetite. GIP receptor activation may also improve adipocyte lipid handling and reduce ectopic fat deposition. SURPASS-2 (Frias et al., New England Journal of Medicine, 2021) showed superior HbA1c and weight reductions with tirzepatide versus semaglutide 1 mg.

SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022) reported weight loss of up to about 21% at 72 weeks in adults with obesity. The 10 mg presentation supports studies of body composition, liver fat, insulin sensitivity and cardiovascular markers. It is also used to compare dual agonism with triple agonism and with GLP-1 monotherapy. The 10 mg vial allows multi-arm studies at intermediate exposures. Because tirzepatide adsorbs to surfaces, use low-binding tubes and include a carrier protein if the assay permits. For long-term storage, keep the lyophilised vial desiccated at -20C and allow it to equilibrate to room temperature before opening to prevent condensation.

Reconstitute with bacteriostatic water, mix gently, and avoid vortexing or repeated freeze-thaw cycles. Key questions concern the dose-response separation of efficacy from gastrointestinal effects, the durability of weight loss after discontinuation, and the effect on lean mass and bone density. For research use only. This material is not a drug, food or cosmetic and must not be administered to humans or animals outside an approved research protocol.